Clinical Trial Results:
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination with 5µg Tiotropium Bromide (Delivered by the Respimat® Inhaler) compared with 5µg Tiotropium Bromide Monoproduct (Delivered by the Respimat® Inhaler) in Patients with COPD
Summary
|
|
EudraCT number |
2007-005087-26 |
Trial protocol |
DE |
Global completion date |
10 Feb 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Mar 2016
|
First version publication date |
09 Mar 2016
|
Other versions |
|
Summary report(s) |
Trial Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.